BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23399736)

  • 1. Decreased mucosal sulfide detoxification capacity in patients with Crohn's disease.
    Arijs I; Vanhove W; Rutgeerts P; Schuit F; Verbeke K; De Preter V
    Inflamm Bowel Dis; 2013 Apr; 19(5):E70-2. PubMed ID: 23399736
    [No Abstract]   [Full Text] [Related]  

  • 2. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
    Tang R; Yang G; Zhang S; Wu C; Chen M
    Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis.
    De Preter V; Arijs I; Windey K; Vanhove W; Vermeire S; Schuit F; Rutgeerts P; Verbeke K
    Inflamm Bowel Dis; 2012 Dec; 18(12):2371-80. PubMed ID: 22434643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn's disease.
    Neves AR; Castelo-Branco MT; Figliuolo VR; Bernardazzi C; Buongusto F; Yoshimoto A; Nanini HF; Coutinho CM; Carneiro AJ; Coutinho-Silva R; de Souza HS
    Inflamm Bowel Dis; 2014 Mar; 20(3):444-57. PubMed ID: 24412990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn's disease and ulcerative colitis.
    Jugde F; Alizadeh M; Boissier C; Chantry D; Siproudhis L; Corbinais S; Quelvennec E; Dyard F; Campion JP; Gosselin M; Bretagne JF; Sémana G; Heresbach D
    Eur Cytokine Netw; 2001; 12(3):468-77. PubMed ID: 11566628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts.
    Bajaj-Elliott M; Breese E; Poulsom R; Fairclough PD; MacDonald TT
    Am J Pathol; 1997 Nov; 151(5):1469-76. PubMed ID: 9358773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease.
    Autschbach F; Giese T; Gassler N; Sido B; Heuschen G; Heuschen U; Zuna I; Schulz P; Weckauf H; Berger I; Otto HF; Meuer SC
    Virchows Arch; 2002 Nov; 441(5):500-13. PubMed ID: 12447682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
    Stadnicki A; Mazurek U; Plewka D; Wilczok T
    Int Immunopharmacol; 2003 Jul; 3(7):939-44. PubMed ID: 12810351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Runt-related transcription factor 3 is associated with ulcerative colitis and shows epistasis with solute carrier family 22, members 4 and 5.
    Weersma RK; Zhou L; Nolte IM; van der Steege G; van Dullemen HM; Oosterom E; Bok L; Peppelenbosch MP; Faber KN; Kleibeuker JH; Dijkstra G
    Inflamm Bowel Dis; 2008 Dec; 14(12):1615-22. PubMed ID: 18668679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis.
    Raddatz D; Middel P; Bockemühl M; Benöhr P; Wissmann C; Schwörer H; Ramadori G
    Aliment Pharmacol Ther; 2004 Jan; 19(1):47-61. PubMed ID: 14687166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current evidence for vitamin D in intestinal function and disease.
    Hassanshahi M; Anderson PH; Sylvester CL; Stringer AM
    Exp Biol Med (Maywood); 2019 Sep; 244(12):1040-1052. PubMed ID: 31366237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
    Szewczuk MR; Depew WT
    Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Morphological and immunohistochemical characteristic of oral mucosa in patients with inflammatory bowel disease].
    Kvetnoĭ IM; Robakidze NS; Kostiuchek IN; Shchukina OB; Proshchaev KI
    Adv Gerontol; 2010; 23(3):371-4. PubMed ID: 21137207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of the roles of sulfide oxidase and rhodanese in the detoxification of sulfide by the colonic mucosa.
    Wilson K; Mudra M; Furne J; Levitt M
    Dig Dis Sci; 2008 Jan; 53(1):277-83. PubMed ID: 17551834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular changes in ulcerative colitis and Leśniowski-Crohn's disease.
    Zurawski J; Woźniak A; Salwa-Zurawska W; Kaczmarek E; Majewski P
    Pol J Pathol; 2007; 58(1):13-21. PubMed ID: 17585538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
    Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
    Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease.
    Palone F; Vitali R; Cucchiara S; Pierdomenico M; Negroni A; Aloi M; Nuti F; Felice C; Armuzzi A; Stronati L
    Inflamm Bowel Dis; 2014 Aug; 20(8):1448-57. PubMed ID: 24983978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity.
    Walsh A; Palmer R; Travis S
    Gastrointest Endosc Clin N Am; 2014 Jul; 24(3):367-78. PubMed ID: 24975528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.